Regnante Keith 4
4 · Keros Therapeutics, Inc. · Filed Jan 8, 2024
Insider Transaction Report
Form 4
Regnante Keith
CHIEF FINANCIAL OFFICER
Transactions
- Exercise/Conversion
Common Stock
2023-11-04$16.00/sh+40,000$640,000→ 40,000 total - Sale
Common Stock
2023-11-04$45.29/sh−40,000$1,811,600→ 0 total - Exercise/Conversion
Employee Stock Option (right to buy)
2024-01-04−40,000→ 53,622 totalExercise: $16.00Exp: 2030-04-06→ Common Stock (40,000 underlying)
Footnotes (2)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023.
- [F2]One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.